for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Heat Biologics Inc

HTBX.OQ

Latest Trade

6.91USD

Change

-0.29(-4.03%)

Volume

90,911

Today's Range

6.84

 - 

7.15

52 Week Range

4.90

 - 

30.10

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
7.20
Open
7.15
Volume
90,911
3M AVG Volume
21.51
Today's High
7.15
Today's Low
6.84
52 Week High
30.10
52 Week Low
4.90
Shares Out (MIL)
25.25
Market Cap (MIL)
181.82
Forward P/E
-5.83
Dividend (Yield %)
--

Next Event

Q2 2021 Heat Biologics Inc Earnings Release

Latest Developments

More

Heat Biologics Reports Q1 Loss Per Share Of $0.31

Heat Biologics Announces New Preclinical Data On Ptx-35, Demonstrating Decreased Regulatory T-Cell (Treg) Activity And Delayed Tumor Progression

Heat Biologics Announces Positive Interim Survival Data From Ongoing HS-110 Phase 2 Non-Small Cell Lung Cancer Trial

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Heat Biologics Inc

Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.

Industry

Biotechnology & Drugs

Contact Info

627 DAVIS DRIVE, SUITE 400

MORRISVILLE, NC

27560

United States

+1.919.2407133

http://www.heatbio.com/

Executive Leadership

Jeffrey Alan Wolf

Chairman of the Board, President, Chief Executive Officer

William L. Ostrander

Chief Financial Officer

John K. A. Prendergast

Lead Independent Director

John P. Monahan

Independent Director

Edward B. Smith

Independent Director

Key Stats

2.00 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-6.300

2019

-4.200

2020

-1.630

2021(E)

-1.238
Price To Earnings (TTM)
--
Price To Sales (TTM)
70.34
Price To Book (MRQ)
1.32
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.18
LT Debt To Equity (MRQ)
0.10
Return on Investment (TTM)
-31.83
Return on Equity (TTM)
-30.32

Latest News

Latest News

BRIEF-Heat Biologics Says First Patient Treated In Co's First-In-Human Phase 1 Clinical Trial Evaluating PTX-35

* HEAT BIOLOGICS - FIRST PATIENT HAS BEEN TREATED IN CO'S FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL EVALUATING PTX-35

BRIEF-Heat Biologics Announces FDA Clearance Of Investigational New Drug Application For PTX-35

* HEAT BIOLOGICS - ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR PTX-35

BRIEF-Heat Biologics Inc says It Had Cash, Cash Equivalents And Short-Term Investments Of $35.5 Million As Of June 1, 2020

* HEAT BIOLOGICS INC - IT HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $35.5 MILLION AS OF JUNE 1, 2020

BRIEF-Heat Biologics Presents Positive Survival Benefit For Hs-110 In Combination With Nivolumab In Phase 2 Lung Cancer Trial At 2020 Asco Annual Meeting

* HEAT BIOLOGICS PRESENTS POSITIVE SURVIVAL BENEFIT FOR HS-110 IN COMBINATION WITH NIVOLUMAB IN PHASE 2 LUNG CANCER TRIAL AT 2020 ASCO ANNUAL MEETING

BRIEF-Heat Biologics Announces Collaboration with Waisman Biomanufacturing to Manufacture COVID-19 Vaccine

* HEAT BIOLOGICS INC - COLLABORATING WITH WAISMAN BIOMANUFACTURING TO ESTABLISH A PARTNERSHIP FOR MANUFACTURE OF CO'S COVID-19 VACCINE Source text for Eikon: Further company coverage:

BRIEF-Heat Biologics Plans To Initiate Type B End Of Phase 2 Meeting With FDA To Discuss Registration Strategy For Hs-110

* HEAT BIOLOGICS INC - PLAN TO INITIATE TYPE B END OF PHASE 2 MEETING WITH FDA TO DISCUSS REGISTRATION STRATEGY FOR HS-110 Source text for Eikon: Further company coverage:

BRIEF-Heat Biologics Announces Strategy & Anticipated Q2 Milestones For Covid-19 Vaccine Program

* HEAT BIOLOGICS - ANNOUNCED STRATEGY & ANTICIPATED Q2 2020 MILESTONES FOR COVID-19 VACCINE PROGRAM

BRIEF-Heat Biologics Terminates Collaboration With University Of Miami For Development Of A Covid-19 Point Of Care Diagnostic

* HEAT BIOLOGICS - TERMINATED ITS COLLABORATION WITH UNIVERSITY OF MIAMI FOR DEVELOPMENT OF A COVID-19 POINT OF CARE DIAGNOSTIC

BRIEF-Heat Biologics Inc Entered Into Amendment To That Certain At Market Issuance Sales Agreement Between Co And B. Riley FBR, Inc.

* HEAT BIOLOGICS INC - ON APRIL 23, ENTERED INTO AMENDMENT TO THAT CERTAIN AT MARKET ISSUANCE SALES AGREEMENT BETWEEN CO AND B. RILEY FBR, INC.

BRIEF-Heat Biologics Inc Files For Mixed Shelf Of Up To $150 Million

* HEAT BIOLOGICS INC FILES FOR MIXED SHELF OF UP TO $150 MILLION – SEC FILING Source text: [https://bit.ly/2zli0jD] Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Heat Biologics Entered Into Collaboration With University Of Miami To Develop A Coronavirus COVID-19 Point-Of-Care Diagnostic Test

* HEAT BIOLOGICS INC - ENTERED INTO COLLABORATION WITH UNIVERSITY OF MIAMI TO DEVELOP A CORONAVIRUS COVID-19 POINT-OF-CARE DIAGNOSTIC TEST

BRIEF-Heat Biologics Says WHO Has Added Co's Covid-19 Vaccine To "Draft Landscape Of Covid-19 Candidate Vaccines"

* HEAT BIOLOGICS- WHO HAS ADDED CO'S COVID-19 VACCINE TO ITS "DRAFT LANDSCAPE OF COVID-19 CANDIDATE VACCINES" TARGETING SARS-COV-2 CORONAVIRUS Source: (http://bit.ly/2xIMBqB) Further company coverage:

BRIEF-Heat Biologics Says Engaged A Firm To Assist In Securing Government Funding To Develop Coronavirus Vaccine

* HEAT BIOLOGICS - ON MARCH 6, ENGAGED A FIRM TO ASSIST IN SECURING GOVERNMENT FUNDING FOR PROGRAM TO DEVELOP CORONAVIRUS VACCINE - SEC FILING Source: (https://bit.ly/2xp2aDD) Further company coverage:

BRIEF-Heat Biologics To Collaborate With University Of Miami To Develop Vaccine Against COVID-19 Coronavirus

* HEAT BIOLOGICS INC - ANNOUNCES RESEARCH COLLABORATION WITH UNIVERSITY OF MIAMI TO DEVELOP VACCINE DESIGNED TO PROTECT AGAINST COVID-19 CORONAVIRUS Source: (https://bit.ly/3avVDW9) Further company coverage:

BRIEF-Heat Biologics Says Filed Provisional Patent Application That Applies Immune System Activating Technology For Treating/Preventing Infection With SARS-CoV-2 Virus That Causes COVID-19

* HEAT BIOLOGICS - FILED PROVISIONAL PATENT APPLICATION THAT APPLIES IMMUNE SYSTEM ACTIVATING TECHNOLOGY FOR TREATING/PREVENTING INFECTION WITH SARS-COV-2 VIRUS THAT CAUSES COVID-19 Source text: (http://bit.ly/2VzjcJr) Further company coverage:

Heat-stable drug could save thousands from post-childbirth bleeding: WHO

A new formulation of a drug to prevent excessive bleeding in women after they give birth could save thousands of lives in poorer countries, according to a study co-led by the World Health Organization (WHO).

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up